Recognizing 100 Years of Thrombotic Thrombocytopenic Purpura
Over the last century, the understanding and treatment of TTP have evolved significantly. We are proud of the part we play in addressing unmet needs for people living with TTP.
Thrombotic Thrombocytopenic Purpura (TTP) is a rare, immune-mediated blood disorder that causes small blood clots in blood vessels throughout the body. These clots can cause serious health problems, including bruising, low platelet count, and organ dysfunction that can result in serious events like seizures, heart attacks, or strokes.
100 years ago, TTP was first described by a physician. As we reflect on the years of progress in understanding TTP, we’re proud of our role in furthering treatment options for patients.
Anise’s Story
After experiencing bruising, low platelet count, and pain, Anise was admitted to the emergency room multiple times. After a hospital visit where she suffered a stroke, Anise was finally diagnosed with TTP. Her long journey to diagnosis and her experience since have inspired Anise to become vocal in the TTP community, encouraging others living with the disease to advocate for themselves. Hear her story below and learn more about TTP.
At Sanofi, we chase the miracles of science to improve people’s lives and our dedication to the TTP community is evidence of that pursuit.